TR201908669T4 - N-desülfatlanmış glikozaminoglikanların türevleri ve ilaç olarak kullanımı. - Google Patents

N-desülfatlanmış glikozaminoglikanların türevleri ve ilaç olarak kullanımı. Download PDF

Info

Publication number
TR201908669T4
TR201908669T4 TR2019/08669T TR201908669T TR201908669T4 TR 201908669 T4 TR201908669 T4 TR 201908669T4 TR 2019/08669 T TR2019/08669 T TR 2019/08669T TR 201908669 T TR201908669 T TR 201908669T TR 201908669 T4 TR201908669 T4 TR 201908669T4
Authority
TR
Turkey
Prior art keywords
glycosaminoglycan
derivatives
desulfated
relates
drugs
Prior art date
Application number
TR2019/08669T
Other languages
English (en)
Inventor
Naggi Annamaria
Torri Giangiacomo
Original Assignee
Novahealth Biosystems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novahealth Biosystems Llc filed Critical Novahealth Biosystems Llc
Publication of TR201908669T4 publication Critical patent/TR201908669T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Buluş, N-desülfatlanmış ve opsiyonel olarak 2-O-desülfatlanmış glikozaminoglikan türevlerine ilişkin olup, burada bitişik diollerin ve OH/NH2'nin en azından parçası ilgili aldehite dönüştürülmüştür ve bu aldehitler daha sonra ilgili alkole indirgenmiştir. Bu ürünler heparanaz engelleyici aktiviteler ve anti-tümör aktivite ile donatılır. Bahsedilen glikozaminoglikan türevleri doğal veya sentetik glikozaminoglikandan, tercihen fraksiyone edilmemiş heparin, düşük moleküler ağırlıklı heparinler (LMWHs), heparan sülfat veya bunların türevlerinden elde edilir. Bu buluş ayrıca, bunların hazırlanma işlemine ve ayrıca bilinen yerleşik ilaçlar ve tedaviler ile kombinasyon halinde ilaçların etkin maddeleri olarak kullanımlarına ilişkindir. Mevcut buluş ayrıca, bir glikozaminoglikanın glikozamin kalıntılarının C 2 -C 3 bağını bahsedilen glikozaminoglikanın oksidasyonu ile kırmak için olan bir işleme ilişkindir.
TR2019/08669T 2013-10-31 2014-10-23 N-desülfatlanmış glikozaminoglikanların türevleri ve ilaç olarak kullanımı. TR201908669T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000005A ITLO20130005A1 (it) 2013-10-31 2013-10-31 Derivati di glucosamminoglicani n-desolfatati e loro uso come farmaci

Publications (1)

Publication Number Publication Date
TR201908669T4 true TR201908669T4 (tr) 2019-07-22

Family

ID=49683857

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08669T TR201908669T4 (tr) 2013-10-31 2014-10-23 N-desülfatlanmış glikozaminoglikanların türevleri ve ilaç olarak kullanımı.

Country Status (14)

Country Link
US (2) US10875936B2 (tr)
EP (2) EP3375792B9 (tr)
JP (1) JP6753610B2 (tr)
KR (1) KR102007554B1 (tr)
CN (2) CN108912237B (tr)
CY (2) CY1121087T1 (tr)
DK (2) DK3063177T3 (tr)
ES (2) ES2687900T3 (tr)
HK (2) HK1222873A1 (tr)
IT (1) ITLO20130005A1 (tr)
PL (2) PL3063177T3 (tr)
PT (2) PT3063177T (tr)
TR (1) TR201908669T4 (tr)
WO (1) WO2015062951A1 (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111670038B (zh) * 2018-02-02 2024-01-26 深圳市海普瑞药业集团股份有限公司 糖胺聚糖衍生物及其制备方法和用途
CN111019014A (zh) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 一种那曲肝素钙的制备工艺
CN114901702B (zh) * 2019-12-27 2024-01-09 深圳市海普瑞药业集团股份有限公司 一种糖胺聚糖衍生物及其应用
WO2024012972A1 (en) 2022-07-14 2024-01-18 Centro Alta Tecnologia Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni S.R.L. Synthetic hexasaccharides mimics of heparin showing heparanase inhibition activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230582B (it) 1988-10-21 1991-10-28 Opocrin S P A Lab Farmabiologi Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5583121A (en) * 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
IT1316986B1 (it) * 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
CN1197587C (zh) * 2000-06-09 2005-04-20 中国科学院上海细胞生物学研究所 N－位脱硫酸肝素在预防和治疗炎症中的应用
SK288335B6 (sk) 2001-09-12 2016-02-02 Sigma-Tau Research Switzerland S.A. Čiastočne alebo úplne N-desulfatovaný, N-reacetylovaný heparín, spôsob jeho prípravy, jeho použitie na prípravu liečiva s inhibičným účinkom na heparanázu, s antiangiogénnym a protizápalovým účinkom a farmaceutický prostriedok s jeho obsahom
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
CN102924627A (zh) * 2012-11-19 2013-02-13 江南大学 一种具有抗肿瘤活性的低抗凝肝素的制备方法

Also Published As

Publication number Publication date
WO2015062951A1 (en) 2015-05-07
DK3375792T3 (da) 2019-06-24
ITLO20130005A1 (it) 2015-05-01
HK1222873A1 (zh) 2017-07-14
US20160237178A1 (en) 2016-08-18
CN108912237A (zh) 2018-11-30
PT3063177T (pt) 2018-10-19
US20210332162A9 (en) 2021-10-28
PT3375792T (pt) 2019-06-27
ES2731582T3 (es) 2019-11-18
US10875936B2 (en) 2020-12-29
CN108912237B (zh) 2021-04-13
US20200216577A1 (en) 2020-07-09
PL3063177T3 (pl) 2018-11-30
DK3063177T3 (en) 2018-10-08
EP3063177B1 (en) 2018-08-15
CY1121087T1 (el) 2019-12-11
US20210054108A2 (en) 2021-02-25
CN105814086B (zh) 2018-09-28
KR20160105969A (ko) 2016-09-08
EP3063177A1 (en) 2016-09-07
PL3375792T3 (pl) 2019-09-30
ES2687900T3 (es) 2018-10-29
CN105814086A (zh) 2016-07-27
CY1121728T1 (el) 2020-07-31
HK1254817B (zh) 2020-03-27
JP6753610B2 (ja) 2020-09-09
EP3375792B9 (en) 2019-11-13
KR102007554B1 (ko) 2019-08-05
JP2017507210A (ja) 2017-03-16
EP3375792B1 (en) 2019-05-15
US11248063B2 (en) 2022-02-15
EP3375792A1 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
CY1121728T1 (el) Παραγωγα ν-αποθειωμενων γλουκοζαμινογλυκανων και χρηση ως φαρμακα
MX2014007122A (es) Nuevos glucosaminoglucanos con baja actividad anticoagulante.
MX2014000354A (es) Quinazolinas sustituidas, su preparacion y su uso en composiciones farmaceuticas.
WO2015048547A3 (en) Methods for using and biomarkers for ampk-activating compounds
WO2012078558A3 (en) microRNAs AS NEW THERAPEUTIC TARGETS FOR THE PREVENTION AND/OR TREATMENT OF RETINOPATHY
WO2012125872A3 (en) Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof
BR112014026703A2 (pt) inibidores de dna-pk
BR112015013124A2 (pt) novos derivados de piridina
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
WO2012068383A3 (en) ncRNA AND USES THEREOF
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
GB2535414A (en) Sanitary tissue products with superior machine direction elongation and foreshortening properties and methods for making same
PH12014501387B1 (en) Low anticoagulant heparins
WO2011098962A3 (fr) Polysaccharides anioniques fonctionnalisés par au moins deux groupements hydrophobes portés par un spacer au moins trivalent
WO2012158780A3 (en) Lung cancer signature
MX2019006620A (es) Composiciones de polisacaridos y metodos de uso.
WO2013006335A3 (en) Methods and compositions useful for treating fitzpatrick type iv, v or vi skin
JO3676B1 (ar) مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
BR112012022337A2 (pt) composição e respectivos método de preparação e uso de quantidade eficaz
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
BR112015014964A2 (pt) novos derivados de metisergida
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
WO2015023508A8 (en) Methods for improving asthma symptoms using benralizumab
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
IN2014CN04861A (tr)